NECLIFE

Nectar Lifesciences financials

Market cap
₹232 Cr
Sector
Healthcare

What Nectar Lifesciences Limited does

Nectar Lifesciences manufactures active pharmaceutical ingredients (APIs) and finished dosage formulations (tablets, capsules, injectables and dry syrups) for cephalosporin and non-cephalosporin antibiotics, alongside empty hard gelatin capsules. Manufacturing runs across two API units in Derabassi, Punjab and a formulation plus capsule unit cluster in Barotiwala, Himachal Pradesh, with several facilities holding approvals from regulators including USFDA, EU-GMP, Japan's PMDA and Korea's KFDA. The company sells domestically and exports to more than 45 countries, with expanding focus on regulated markets such as Europe, Japan, Korea and China. In July 2025 (after FY25 year-end), the board approved a slump sale of the company's API/formulations business to Ceph Lifesciences Private Limited, along with a separate sale of its menthol business assets.

Segments

  • Active Pharmaceutical Ingredients (API)
  • Finished Dosage Forms (FDF)
  • Empty Hard Gelatin Capsules
  • Menthol business
Manufacturing plants
4 (API Units I & II — Derabassi, Punjab; Formulation Unit + Capsule Unit — Barotiwala, HP)
API manufacturing area (Units I & II)
~436,000 sq. meter combined (Derabassi, Punjab)
Export countries
45+
Employees
2,000+
Drug Master Filings (DMFs) filed globally
44
Regulatory approvals (API facilities)
USFDA, EU-GMP, Japan PMDA, Korea KFDA, Brazil ANVISA
Founded 1995Headquarters Chandigarh, IndiaEmployees 2,000 (Q3 FY25 (Dec 2024)) Company website

Quarterly results

Q1 FY27: revenue down 100.0%, net profit up 76.2% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue6 0 0 5 1 −83%0 1 0 −100%
EBITDA-1 0 0 -1 1 +200%-2 -57 -27 −2600%
Net profit6 8 -130 -63 -176 −3033%14 +75%-68 +48%-15 +76%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Performance −19.7% 1Y

₹10.0₹15.0₹20.0Sept 25Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26

1Y: ₹14.32 on 10 Sept 2025 → ₹11.5. High ₹22.25 (23 Dec 2025), low ₹9.3 (30 Mar 2026).

Financials, as filed

Revenue fell 83.4% a year over 3 years, FY23 to FY26. Operating margin narrowed to -842.9%.

Year endingFY23FY24FY25FY26
Revenue₹1.5k Cr₹1.7k Cr₹365 Cr₹7 Cr
Operating profit₹54 Cr₹153 Cr₹39 Cr₹-59 Cr
Operating margin3.5%9.1%10.7%-842.9%
Interest₹79 Cr₹88 Cr₹20 Cr₹36 Cr
Depreciation₹60 Cr₹60 Cr₹15 Cr₹1 Cr
Net profit₹-23 Cr₹6 Cr₹-113 Cr₹-293 Cr
Net margin-1.5%0.4%-31.0%-4185.7%
Cash from operations₹134 Cr₹225 Cr₹169 Cr₹-349 Cr
Free cash flow₹183 Cr₹195 Cr₹126 Cr₹-341 Cr
ROCE0.0%6.0%-5.0%0.0%
How to read this

From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.

Balance sheet

Year endingFY21FY22FY23FY24FY25FY26
Equity capital₹22 Cr₹22 Cr₹22 Cr₹22 Cr₹22 Cr₹19 Cr
Reserves₹1.0k Cr₹1.1k Cr₹1.0k Cr₹1.1k Cr₹694 Cr₹563 Cr
Borrowings₹903 Cr₹860 Cr₹754 Cr₹629 Cr₹459 Cr₹0 Cr
Other liabilities₹423 Cr₹443 Cr₹371 Cr₹476 Cr₹639 Cr₹39 Cr
Total liabilities₹2.4k Cr₹2.4k Cr₹2.2k Cr₹2.2k Cr₹1.8k Cr₹622 Cr
Fixed assets₹772 Cr₹723 Cr₹662 Cr₹804 Cr₹28 Cr₹105 Cr
Capital work in progress₹99 Cr₹85 Cr₹78 Cr₹57 Cr₹0 Cr₹0 Cr
Investments₹1 Cr₹1 Cr₹1 Cr₹1 Cr₹1 Cr₹13 Cr
Other assets₹1.5k Cr₹1.6k Cr₹1.4k Cr₹1.3k Cr₹1.8k Cr₹504 Cr
Total assets₹2.4k Cr₹2.4k Cr₹2.2k Cr₹2.2k Cr₹1.8k Cr₹622 Cr
How to read this

As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.

Who owns it

As disclosed at Jun 2026

Since Jun 2025, the public trimmed −10.55 pp while promoters added +7.31 pp. The shareholder count grew 3% to 73,834.

Promoters
51.8%
FIIs
0.5%
DIIs
0.0%
Government
3.8%
Public
43.9%

Since Jun 2025

  • Public −10.55 pp
  • Promoters +7.31 pp
  • Government +3.73 pp

How it drifted, 12 quarters

Over this window the public went from 28.2% to 43.9% — +15.7 pp.

Sep '23Dec '24Jun '26

Ownership split by quarter, oldest first. Sep '23: Promoters 55.8%, FIIs 16.0%, Government 0.0%, Public 28.2%.Dec '23: Promoters 55.8%, FIIs 16.1%, Government 0.0%, Public 28.1%.Mar '24: Promoters 55.8%, FIIs 17.0%, Government 0.0%, Public 27.2%.Jun '24: Promoters 55.8%, FIIs 16.6%, Government 0.0%, Public 27.6%.Sep '24: Promoters 55.8%, FIIs 3.2%, Government 0.0%, Public 40.9%.Dec '24: Promoters 44.5%, FIIs 0.7%, Government 0.0%, Public 54.7%.Mar '25: Promoters 44.5%, FIIs 1.6%, DIIs 0.1%, Government 0.0%, Public 53.6%.Jun '25: Promoters 44.5%, FIIs 0.8%, DIIs 0.2%, Government 0.0%, Public 54.5%.Sep '25: Promoters 44.9%, FIIs 0.6%, DIIs 0.1%, Government 0.0%, Public 54.4%.Dec '25: Promoters 44.9%, FIIs 0.5%, Government 5.8%, Public 48.7%.Mar '26: Promoters 51.8%, FIIs 0.6%, DIIs 0.0%, Government 4.0%, Public 43.5%.Jun '26: Promoters 51.8%, FIIs 0.5%, DIIs 0.0%, Government 3.8%, Public 43.9%.

Who was buying across the market this quarter →

Who is on the register

Named in the Jun 2026 filing

Every holder of Nectar Lifesciences Limited above SEBI's 1% disclosure line, and what changed since Mar 2026.

HolderStakeChange
Sanjiv Goyal 24.63%unchanged
Sanjiv (Huf) - Karta Sanjiv Goyal 22.46%unchanged
Raman Goyal 4.76%unchanged
Rajasthan Global Securities Private Limited NBFC / DFI3.73%−0.28 pp
Nectar Organics Private Limited 0.00%unchanged
Orient Alloys Private Limited 0.00%unchanged

A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.

Learn to analyse Nectar Lifesciences Limited

Guides on how to read this kind of business and the numbers that matter.